SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934 (Amendment No. 10)*
Chiron Corporation
..............................................................................
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
..............................................................................
(Title of Class of Securities)
170040109
..............................................................................
(CUSIP Number)
Dr. Herbert Gut Philip A. Gelston, Esq.
Novartis Pharma AG Cravath, Swaine & Moore
Lichtstrasse 35 Worldwide Plaza
CH-4002, Basel 825 Eighth Avenue
Switzerland New York, New York 10019
41-61-324-1111 (212) 474-1000
..............................................................................
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
October 6, 2000
..............................................................................
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box. [ ]
NOTE: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule 240.13d-7
for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Page 1 of 15
<PAGE>
CUSIP No. 170040109
------------------------------------------------------------------------------
1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons
(entities only)
Novartis Biotech Partnership, Inc. 06-1415318
------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
------------------------------------------------------------------------------
3) SEC Use Only
------------------------------------------------------------------------------
4) Source of Funds (See Instructions) AF
------------------------------------------------------------------------------
5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
------------------------------------------------------------------------------
6) Citizenship or Place of Organization Delaware
------------------------------------------------------------------------------
Numbers of (7) Sole Voting Power 0
Shares ------------------------------------------------------------
Beneficially (8) Shared Voting Power 131,645,894
Owned by ------------------------------------------------------------
Each Reporting (9) Sole Dispositive Power 0
Person With ------------------------------------------------------------
(10) Shared Dispositive Power 131,645,894
------------------------------------------------------------------------------
11) Aggregate Amount Beneficially Owned by Each Reporting Person 131,645,894
------------------------------------------------------------------------------
12) Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions)
------------------------------------------------------------------------------
13) Percent of Class Represented by Amount in Row (11) 53%
------------------------------------------------------------------------------
14) Type of Reporting Person (See Instructions) CO
Page 2 of 15
<PAGE>
CUSIP No. 170040109
------------------------------------------------------------------------------
1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons
(entities only)
Novartis Corporation 13-1834433
------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
------------------------------------------------------------------------------
3) SEC Use Only
------------------------------------------------------------------------------
4) Source of Funds (See Instructions) AF
------------------------------------------------------------------------------
5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) [ ]
------------------------------------------------------------------------------
6) Citizenship or Place of Organization New York
------------------------------------------------------------------------------
Numbers of (7) Sole Voting Power 0
Shares ------------------------------------------------------------
Beneficially (8) Shared Voting Power 131,653,350
Owned by ------------------------------------------------------------
Each Reporting (9) Sole Dispositive Power 0
Person With ------------------------------------------------------------
(10) Shared Dispositive Power 131,653,350
------------------------------------------------------------------------------
11) Aggregate Amount Beneficially Owned by Each Reporting Person 131,653,350
------------------------------------------------------------------------------
12) Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions)
------------------------------------------------------------------------------
13) Percent of Class Represented by Amount in Row (11) 53%
------------------------------------------------------------------------------
14) Type of Reporting Person (See Instructions) CO
Page 3 of 15
<PAGE>
CUSIP No. 170040109
------------------------------------------------------------------------------
1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons
(entities only)
Novartis Pharma AG
------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
------------------------------------------------------------------------------
3) SEC Use Only
------------------------------------------------------------------------------
4) Source of Funds (See Instructions) WC
------------------------------------------------------------------------------
5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
------------------------------------------------------------------------------
6) Citizenship or Place of Organization Switzerland
------------------------------------------------------------------------------
Numbers of (7) Sole Voting Power 0
Shares ------------------------------------------------------------
Beneficially (8) Shared Voting Power 5,469,770
Owned by ------------------------------------------------------------
Each Reporting (9) Sole Dispositive Power 0
Person With ------------------------------------------------------------
(10) Shared Dispositive Power 5,469,770
------------------------------------------------------------------------------
11) Aggregate Amount Beneficially Owned by Each Reporting Person 5,469,770
------------------------------------------------------------------------------
12) Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions)
------------------------------------------------------------------------------
13) Percent of Class Represented by Amount in Row (11) 2%
------------------------------------------------------------------------------
14) Type of Reporting Person (See Instructions) CO
Page 4 of 15
<PAGE>
CUSIP No. 170040109
------------------------------------------------------------------------------
1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons
(entities only)
Novartis AG
------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
------------------------------------------------------------------------------
3) SEC Use Only
------------------------------------------------------------------------------
4) Source of Funds (See Instructions) WC
------------------------------------------------------------------------------
5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
------------------------------------------------------------------------------
6) Citizenship or Place of Organization Switzerland
------------------------------------------------------------------------------
Numbers of (7) Sole Voting Power 0
Shares ------------------------------------------------------------
Beneficially (8) Shared Voting Power 137,123,120
Owned by ------------------------------------------------------------
Each Reporting (9) Sole Dispositive Power 0
Person With ------------------------------------------------------------
(10) Shared Dispositive Power 137,123,120
------------------------------------------------------------------------------
11) Aggregate Amount Beneficially Owned by Each Reporting Person 137,123,120
------------------------------------------------------------------------------
12) Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions)
------------------------------------------------------------------------------
13) Percent of Class Represented by Amount in Row (11) 55%
------------------------------------------------------------------------------
14) Type of Reporting Person (See Instructions) CO
Page 5 of 15
<PAGE>
Item 1. Security and Issuer.
This amendment to Schedule 13D relates to Common Stock, par value
$0.01 per share (the "Common Stock"), of Chiron Corporation, a Delaware
corporation (the "Company"). Novartis AG (which under Swiss law may be
referred to as AG, SA or Inc.), the successor by consolidation to Ciba-Geigy
Limited ("Novartis"), Novartis Corporation, formerly Ciba-Geigy Corporation
("Novartis Corp"), Novartis Biotech Partnership, Inc., formerly Ciba Biotech
Partnership, Inc. ("Biotech"), and Novartis Pharma AG (which under Swiss law
may be referred to as AG, SA or Inc.) ("Novartis Pharma" and, together with
Novartis, Novartis Corp and Biotech the "Reporting Persons") hereby amend the
Schedule 13D.
Item 2. Identity and Background.
(a), (b), (c) and (f) The name, business address, present principal
occupation or employment and citizenship of the executive officers and members
of the Board of Directors of each of the Reporting Persons is set forth on
Schedule I hereto and is incorporated herein by reference.
(d) and (e) None of the Reporting Persons nor, to the best knowledge
of each of them, any of the persons listed on Schedule I hereto with respect
to each such Reporting Person during the last five years, (i) has been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or (ii) was a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such
proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to,
federal or state securities laws or finding any violation with respect to such
laws.
Item 5. Interest in Securities of the Issuer.
(a) and (b) As of the date of this Amendment, Biotech is the record
holder of 73,842,852 shares of Common Stock. In addition, pursuant to the
Market Price Option Agreement, Biotech or its designee, which must be Novartis
or a subsidiary thereof, has the right to purchase from the Company under
certain circumstances such number of shares of Common Stock as are necessary
for the Reporting Persons to maintain collectively up to a 55% ownership
interest in the Company, which as of October 31, 2000, constituted the right
to purchase an additional 57,803,042 shares, based on 191,511,721 shares of
Common Stock outstanding at October 31, 2000, as reported in the Company's
Quarterly Report on Form 10-Q for the period ended September 30, 2000. Biotech
is the beneficial owner of 131,645,894 shares of Common Stock, or 53% of the
Common Stock, assuming Biotech exercises its right to purchase the additional
shares of Common Stock pursuant to Market Price Option Agreement. Biotech has
shared power to vote or to direct the vote and shared power to dispose or to
direct the disposition with respect to all the shares of Common Stock
beneficially owned by it.
Novartis Corp is the record holder of 7,456 shares of Common Stock. After
adjusting the total number of shares beneficially owned by Novartis Corp to
include the 131,645,894 shares beneficially owned by Biotech, Novartis Corp is
the beneficial owner of 131,653,350 shares of Common Stock or 53% of the
Common Stock, assuming Biotech exercises its right to purchase the additional
shares of Common Stock pursuant to Market Price Option Agreement. Novartis
Corp has shared power to vote or to direct the vote and shared power to
dispose or to direct the disposition with respect to all the shares of Common
Stock beneficially owned by it.
Novartis Pharma is the record holder of 5,469,770 shares of Common Stock,
or 2% of the Common Stock, assuming Biotech exercises its right to purchase
the additional shares of Common Stock pursuant to Market Price Option
Agreement. Novartis Pharma has shared power to vote or to direct the vote and
Page 6 of 15
<PAGE>
shared power to dispose or to direct the disposition with respect to all the
shares of Common Stock beneficially owned by it.
Novartis is the beneficial owner of the shares of Common Stock
beneficially owned by Novartis Pharma, Novartis Corp and Biotech. Novartis
beneficially owns 137,123,120 shares of Common Stock, giving it a 55%
beneficial interest in the Company, assuming Biotech exercises its right to
purchase the additional shares of Common Stock pursuant to Market Price Option
Agreement. Novartis has shared power to vote or to direct the vote and shared
power to dispose or to direct the disposition of the shares of Common Stock
beneficially owned by Biotech, Novartis Corp and Novartis Pharma.
To the best knowledge of each of the Reporting Persons, none of the
persons listed on Schedule I hereto with respect to such Reporting Person is
the beneficial owner of any shares of Common Stock.
(c) Neither the Reporting Persons nor, to the best knowledge of each
of the Reporting Persons, any of the persons listed on Schedule I with respect
to each such Reporting Person has engaged in any transaction in the Common
Stock in the past 60 days.
(d) Not applicable.
(e) Not applicable.
Page 7 of 15
<PAGE>
SCHEDULE I
DIRECTORS AND EXECUTIVE OFFICERS OF
NOVARTIS, NOVARTIS PHARMA, NOVARTIS CORP AND BIOTECH
Directors and Executive Officers of Novartis
The name, address, citizenship and present principal occupation or
employment of each of the directors and executive officers of Novartis are set
forth below. Unless otherwise indicated below, each occupation set forth
opposite an individual's name refers to employment with Novartis.
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ----------- --------------------
Daniel Vasella Switzerland Chairman of the Board of
Chairman of the Board of Directors, Directors,
Chief Executive Officer Chief Executive Officer
c/o Novartis AG
Lichtstrasse 35
CH-4002 Basel, Switzerland
Hans-Jorg Rudloff Germany Head of Investment
Vice Chairman of the Board Banking of the Barclays
c/o Novartis AG Group
Lichtstrasse 35
CH-4002 Basel, Switzerland
Prof. Dr. Helmut Sihler Austria Retired
Vice Chairman of the Board
c/o Novartis AG
Lichtstrasse 35
CH-4002 Basel, Switzerland
Heini Lippuner Switzerland Retired
c/o Novartis AG
Lichtstrasse 35
CH-4002 Basel, Switzerland
Birgit Breuel Germany General Commissioner
c/o Novartis AG Executive Board for the
Lichtstrasse 35 World Exposition EXPO 2000
CH-4002 Basel, Switzerland
Prof. Dr. Peter Burckhardt Switzerland Head of Medical Service at
c/o Novartis AG the University Hospital of
Lichtstrasse 35 Lausanne
CH-4002 Basel, Switzerland
Page 8 of 15
<PAGE>
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ------------ -----------------------
Dr. Hans-Ulrich Doerig Switzerland Chief Executive Officer of
c/o Novartis AG Credit Suisse First Boston
Lichtstrasse 35 in Zurich
CH-4002 Basel, Switzerland
Walter G. Frehner Switzerland Retired
Inzlingerstrasse 276
CH-4125 Riehen, Switzerland
William W. George USA Chairman and Chief
c/o Novartis AG Executive Officer of
Lichtstrasse 35 Medtronic, Inc.,
CH-4002 Basel, Switzerland Minneapolis
Alexandre F. Jetzer Switzerland Consultant
c/o Novartis AG
Lichtstrasse 35
CH-4002 Basel, Switzerland
Pierre Landoldt Switzerland President of the Sandoz
c/o Novartis AG family foundation
Lichtstrasse 35
CH-4002 Basel, Switzerland
Prof. Dr. Rolf M. Zinkernagel Switzerland Professor and Director of
c/o Novartis AG the Institute of
Lichtstrasse 35 Experimental Immunology at
CH-4002 Basel, Switzerland the University of Zurich
Dr. Raymund Breu Switzerland Chief Financial Officer
c/o Novartis AG
Lichstrasse 35
CH-4002 Basel, Switzerland
Thomas Ebeling Germany Chief Executive Officer of
c/o Novartis AG Novartis Pharma
Lichstrasse 35
CH-4002 Basel, Switzerland
Al Piergallini USA Chief Executive Officer of
c/o Novartis Consumer Health, Inc. Novartis Consumer Health
560 Morris Avenue
Summit, NJ 07901-1312, USA
Dr. Urs Barlocher Switzerland Head of International
c/o Novartis AG Coordination, Legal and
Lichstrasse 35 Taxes and Corporate
CH-4002 Basel, Switzerland Security
Page 9 of 15
<PAGE>
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ----------- --------------------
Norman C. Walker Great Britain Head of Human Resources
c/o Novartis AG
Lichstrasse 35
CH-4002 Basel, Switzerland
Dr. Glen Bradley USA Chief Executive Officer of
c/o CIBA Vision Corporation Ciba Vision
11460 Johns Creek Parkway
Duluth/Atlanta, GA 30155, USA
Hans-Beat Gurtler Switzerland Chief Executive Officer
c/o Novartis AG of Novartis Animal Health
Lichstrasse 35
CH-4002 Basel, Switzerland
Dr. Oswald Sellemond Austria Chief Executive Officer of
c/o Novartis AG Novartis Generics
Lichstrasse 35
CH-4002 Basel, Switzerland
Dr. Gilbert Wenzel Germany Head Strategic Planning
c/o Novartis AG
Lichstrasse 35
CH-4002 Basel, Switzerland
Page 10 of 15
<PAGE>
Directors and Executive Officers of Novartis Pharma
The name, address, citizenship and present principal occupation or
employment of each of the directors and executive officers of Novartis Pharma
are set forth below. Unless otherwise indicated below, each occupation set
forth opposite an individual's name refers to employment with Novartis Pharma.
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ----------- --------------------
Daniel Vasella Switzerland Chairman of the Board of
Chairman of the Board of Directors, Directors
Chief Executive Officer
c/o Novartis AG
Lichtstrasse 35
CH-4002 Basel, Switzerland
Dr. Raymund Breu Switzerland Member of the Board of
c/o Novartis AG Directors
Lichstrasse 35
CH-4002 Basel, Switzerland
Thomas Ebeling Germany Member of the Board of
c/o Novartis AG Directors, Head of
Lichstrasse 35 Management
CH-4002 Basel, Switzerland
Page 11 of 15
<PAGE>
Directors and Executive Officers of Novartis Corp
The name, address, citizenship and present principal occupation or
employment of each of the directors and executive officers of Novartis Corp
are set forth below. Unless otherwise indicated below, each occupation set
forth opposite an individual's name refers to employment with Novartis Corp.
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ----------- --------------------
Daniel Vasella Switzerland Chairman of the Board
Chairman of the Board
c/o Novartis AG
Lichtstrasse 35
CH-4002 Basel, Switzerland
Terance Barnett Great Britain Vice Chairman, President
Vice Chairman and Chief Executive Officer
c/o Novartis Corporation
608 Fifth Avenue
New York, NY 10020, USA
Raymund Breu Switzerland Chief Financial Officer,
Director Novartis AG
c/o Novartis AG
Lichstrasse 35
CH-4002 Basel, Switzerland
Thomas Ebeling Germany Chief Executive Officer of
Director Novartis Pharma
c/o Novartis AG
Lichstrasse 35
CH-4002 Basel, Switzerland
Fred Meyer Switzerland Retired
Director
c/o Omnicom Group, Inc.
437 Madison Avenue
New York, NY 10022, USA
Alfred Piergallini USA Chief Executive Officer of
Director Novartis Consumer Health
c/o Novartis Consumer Health, Inc.
560 Morris Avenue
Summit, NJ 07901, USA
Urs Naegelin Switzerland Executive Vice President
c/o Novartis Corporation and Chief Financial Officer
608 Fifth Avenue
New York, NY 10020, USA
Page 12 of 15
<PAGE>
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ----------- --------------------
Robert L. Thompson, Jr. USA Executive Vice President,
c/o Novartis Corporation General Counsel and
608 Fifth Avenue Secretary
New York, NY 10020, USA
Page 13 of 15
<PAGE>
Directors and Executive Officers of Biotech
The name, address, citizenship and present principal occupation or
employment of each of the directors and executive officers of Biotech are set
forth below. Unless otherwise indicated below, each occupation set forth
opposite an individual's name refers to employment with Biotech.
Name, Function and Business Address Citizenship Principal Occupation
----------------------------------- ----------- --------------------
Urs Naegelin Switzerland Executive Vice President
Chairman of the Board and Chief Financial
c/o Novartis Corporation Officer of Novartis
608 Fifth Avenue Corporation
New York, NY 10020, USA
Paulo Costa Brazil Chief Executive Officer of
Vice Chairman of the Board and Novartis Pharmaceuticals
President Corporation
c/o Novartis Pharmaceuticals
Corporation
59 Route 10
East Hanover, NJ 07936
Terance Barnett British Vice Chairman, President
Director and Chief Executive Officer
c/o Novartis Corporation of Novartis Corporation
608 Fifth Avenue
New York, NY 10020, USA
Robert L. Thompson, Jr. USA Executive Vice President,
Vice President and Secretary General Counsel and
c/o Novartis Corporation Secretary of Novartis
608 Fifth Avenue Corporation
New York, NY 10020, USA
Page 14 of 15
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
Dated: January 11, 2001
NOVARTIS BIOTECH PARTNERSHIP, INC.,
by /s/ Jeff Benjamin
--------------------------------
Name: Jeff Benjamin
Title: Vice President
NOVARTIS CORPORATION,
by /s/ Wayne P. Merkelson
--------------------------------
Name: Wayne P. Merkelson
Title: Vice President
NOVARTIS PHARMA AG,
by /s/ Wayne P. Merkelson
--------------------------------
Name: Wayne P. Merkelson
Title: Attorney-in-Fact
Under Power of Attorney
dated January 10, 2001
NOVARTIS AG,
by /s/ Robert L. Thompson, Jr.
--------------------------------
Name: Robert L. Thompson, Jr.
Title: Attorney-in-Fact
Under Power of Attorney
dated January 10, 2001
Page 15 of 15
